WARNING: Internet Explorer does not support modern web standards. This site may not function correctly on this browser and is best viewed on Chrome, Firefox or Edge browsers. Learn More.

Clinical Trials

Current Clinical Trials

Amgen 938 Phase iii

A randomized, Double- masked, Phase 3 study of APB 938 efficacy and safety compared to Aflibercept (Eylea) in adults with Neovascular Age-Related Macular Degeneration 

*Currently enrolling patients. Please contact Keisha Williams, Clinical Research Coordinator 410-337-4500 for additional information.


Regeneron 1934 – PHOTON 

The aim of the PHOTON Study is to evaluate the safety and effectiveness of an investigational drug product for patients with Diabetic Macular Edema.

For further details please call our Clinical Research Coordinator, Keisha Williams, at The National Retina Institute at 410-337-4500.


Upcoming Trials

NRI is in the process of enrolling in several new clinical trials. Details will follow as the enrollment process is completed.


Past Trials

Horizon RVO: “FVF3426g (HORIZON) 

An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability Of Ranibizumab in Subjects with Choroidal Neovascularization (CNV) Secondary to Age Related Macular Degeneration (AMD) Who Have Completed The Treatment Phase Of A Genentech Sponsored Ranibizumab Study

RIDE-FVF4168g

This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in patients with clinically significant macular edema with center involvement (CSME-CI) secondary to diabetes mellitus (Type 1 or 2).

Marina-FVF2598g

An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) Who Have Completed a Genentech-Sponsored Ranibizumab Study

Focus FVF2428g 

This is an open label multicenter extension study for participants who have completed one of the following studies: FVF2428g (NCT00056823), FVF2587g (NCT00061594) or FVF2598g (NCT0056823). Cohort 1 includes patients with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD).

Sailor- FVF3689g

A Phase IIIb, Multicenter Study to Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

RAP

FVF3423s: Phase 1 Study of Intravitreal Lucentis for the Treatment of Stage 1 and 2 Retinal Angiomatous Proliferations

WIRB-Protocol-#20052536

Comparison of Intravitreal Versus Anterior Sub-Tenon’s Injection of Triamcinolone Acetonide for Refractory Diabetic Macular Edema, A Randomized Clinical Trial

WIRB-Protocol-#20051556

An Observational Case Series of Patients Who Underwent Surgery for Full Thickness Macular Holes and Assessed Pre- and Post-Operatively With the Micro Perimeter (MP1)

CLEAR-IT1

A Phase I, Dose-Escalation, Safety, Tolerability, and Bioactivity Study of Intravitreal VEGF Trap in Patients With Neovascular Age-Related Macular Degeneration

EOP1004H

A Phase II/III Randomized, Double Masked, Controlled, Dose-Ranging, Multi-Center Comparative Trial, in Parallel Groups, To Establish the Safety and Efficacy of EYE001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks For 54 Weeks, in Patients With Exudative Age-Related Macular Degeneration (AMD)

AMD-02-99

A Multicenter, Prospective, Randomized, Double-Masked Study Comparing the Safety and Efficacy of Membrane Differential Filtration to a Placebo Treatment in Patients with Non-Exudative Age-Related Macular Degeneration

VGFT-OD-0508

The purpose of this trial is to assess the ocular and systemic safety and tolerability of repeated intravitreal doses of VEGF Trap in patients with subfoveal choroidal neovascularization (CNV) due to AMD. This is a double masked, prospective, randomized study in which five groups of approximately 30 patients meeting the eligibility criteria will be randomly assigned in a balanced ratio to receive a series of intravitreal (IVT) injections of VEGF Trap into the study eye at 4- or 12 -week intervals over a 12-week period.

TG-MV-006

A Randomized, Placebo Controlled, Double-masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion

AG3340-801

A Phase II, Randomized, Double-Masked, Placebo-Controlled Study of the Matrix Metalloproteinase Inhibitor AG3340 in Patients with Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration

AMD-02-99

A Multicenter, Prospective, Randomized, Double-Masked Study Comparing the Safety and Efficacy of Membrane Differential Filtration to a Placebo Treatment in Patients with Non-Exudative Age-Related Macular Degeneration

B7A-MC-MBBK

Protein Kinase C Inhibitor ß – Diabetic Macular Edema Study

B7A-MC-MBBM

Protein Kinase C Inhibitor ß – Diabetic Retinopathy Study

PDTP-920101-OP004

Phase I/II SnET2 Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration

PDTP-920101-OP002

Phase I/II SnET2 Treatment of Subfoveal Choroidal Neovascularization

NAVILAS Laser Use in Retinal Tissue 

Navilas laser is a cutting edge technology, which allows for precise placement of laser sport to retinal tissue. During treatment, the computer system will constantly track patient’s eye movement to direct laser spots more precisely than manual delivery.

Subvisible Micropulse (SVMP) Laser for Neovascular Age Related Macular degeneration (AMD)

The goal of this study is to evaluate beneficial effects of micropulse laser in treatment of wet macular degeneration. Potential benefits for the patients include less number of injections, faster recovery and better vision.

MicroPulse in Retinal Disease 

NRI is on the cutting edge conducting studies evaluating the role of micropulse laser in the treatment of a variety of retinal disorders. Micropulse laser is a gentle laser that does not burn the retina. Instead, it will stimulate the retina to produce beneficial proteins. These proteins in turn will make retina healthier. Numerous studies have shown micropulse laser to be effective for the treatment of a variety of retinal conditions.

CLS1003-302 TOPAZ

A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in combination with an intravitreal Anti-VEGF agent in subjects with retinal vein occlusion.

ALLERGAN CEDAR-150998-005

Safety and efficacy of Abicipar Pegol (AGN–150998-005) in patients with neovascular age-related macular degeneration.

OCULAR PROTEOMICS- The Vitreous Proteome-20060001

NRI conducted  the vitreous proteomics study for over 10 years. The goal of this study was to learn about protein components of the eye and to understand which proteins are associated with each retinal disorder.

GENENTECH (BOULEVARD)-BP29647

A multiple-center, multiple-dose and regimen, randomized, active comparator controlled, double-masked, parallel group, 36 week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in patients with choroidal neovascularization secondary to age-related macular degeneration.

Are You Suffering From Flashes & Floaters?
Schedule a Retina Eye Exam Today!
Patient Portal Login

Our Locations

Columbia

6325 Woodside Court
Suite 125
Columbia, Maryland 21046

(410) 919-4455
Fax: (410) 339-7326
Mon-Fri: 8:30am to 5:00pm
On Call 24/7 (410) 919-4455

Owings Mills

21 Crossroads Drive
Suite 425
Owings Mills, MD 21117

(410) 337-4500
Fax: (410) 339-7326
Mon-Fri: 8am-4:30pm
On Call 24/7 (410) 337-4500

Olney

3402 Olandwood Court
Olney, MD 20832

(410) 919-4455
Fax: (410) 339-7326
Mon-Fri: 8am-4:30pm
On Call 24/7 (410) 772-0445

Catonsville

716 Maiden Choice Lane
Suite 102
Catonsville, MD 21228

(410) 337-4500
Fax: (410) 339-7326
Mon-Fri: 8am-5pm
On Call 24/7 (410) 337-4500